CardioDx Gets Medicare Coverage for Coronary Artery Disease Test | GenomeWeb

NEW YORK (GenomeWeb News) – CardioDx today announced that national Medicare contractor Palmetto GBA will cover the company's Corus CAD gene expression test for coronary artery disease.

Since launching Corus CAD as a laboratory-developed test in 2009, the Palo Alto, Calif.-based cardiovascular genomics testing firm has been collecting clinical utility and cost data to expand insurance reimbursement of the test, which is used to determine which patients have or don't have CAD.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.